News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Daily News VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint Todd Neale November 20, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Conference News ESC 2019 Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis Yael L. Maxwell September 12, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Conference News ESC Heart Failure 2019 Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis Shelley Wood May 26, 2019
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Daily News How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting Shelley Wood February 26, 2019